Last reviewed · How we verify
Ceretec (TECHNETIUM TC 99M EXAMETAZIME)
At a glance
| Generic name | TECHNETIUM TC 99M EXAMETAZIME |
|---|---|
| Sponsor | GE HealthCare |
| Drug class | Radioactive Diagnostic Agent [EPC] |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
| First approval | 1988 |
Approved indications
- Detection of altered cerebral perfusion in stroke
- Localization of intra-abdominal infection and inflammatory bowel disease
Common side effects
- transient increase in blood pressure
- Rash with generalized erythema, facial edema and fever
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ceretec CI brief — competitive landscape report
- Ceretec updates RSS · CI watch RSS
- GE HealthCare portfolio CI